Skip to main content
Top
Published in: Medical Oncology 11/2014

01-11-2014 | Original Paper

TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells

Authors: Yefei Rong, Dansong Wang, Wenchuan Wu, Dayong Jin, Tiantao Kuang, Xiaolin Ni, Lei Zhang, Wenhui Lou

Published in: Medical Oncology | Issue 11/2014

Login to get access

Abstract

Pancreatic cancer is one of the most lethal malignancies, with a poor response to chemotherapy and therefore it is important to identify novel therapeutic targets. TNF receptor-associated factor 6 (TRAF6) , a regulator of NF-κB signaling, has been found recently to be involved in tumorigenesis. However, its function in pancreatic cancer remains poorly understood. Here, we found that the expression of TRAF6 was up-regulated in pancreatic cancer tissues. Moreover, over-expression of TRAF6 in pancreatic cancer cells promoted cell proliferation and migration, whereas down-regulation of TRAF6 impaired the tumorigenicity of pancreatic cancer cells in vitro and in vivo. Mechanistically, TRAF6 regulated the expression of multiple genes involved in cell growth, apoptosis and migration. Our results suggested several important roles of TRAF6 in the pathogenesis of pancreatic cancer. TRAF6 might therefore represent a potential therapeutic target.
Literature
2.
go back to reference Morganti AG, Massaccesi M, Caravatta L, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol. 2010;17:194–205.PubMedCrossRef Morganti AG, Massaccesi M, Caravatta L, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol. 2010;17:194–205.PubMedCrossRef
3.
go back to reference Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancerbinding protein Nf-kappa B by a posttranslational mechanism. Cell. 1986;47:921–8.PubMedCrossRef Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancerbinding protein Nf-kappa B by a posttranslational mechanism. Cell. 1986;47:921–8.PubMedCrossRef
4.
go back to reference Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1986;14:649–83.CrossRef Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1986;14:649–83.CrossRef
5.
go back to reference Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol. 2002;10:153–69.PubMedCrossRef Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol. 2002;10:153–69.PubMedCrossRef
6.
go back to reference Wang W, Abbruzzese JL, Evans DB, et al. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999;5:119–27.PubMed Wang W, Abbruzzese JL, Evans DB, et al. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999;5:119–27.PubMed
7.
go back to reference Chandler NM, Canete JJ, Callery MP. Increased expression of Nfkappa B subunits in human pancreatic cancer cells. J Surg Res. 2004;118:9–14.PubMedCrossRef Chandler NM, Canete JJ, Callery MP. Increased expression of Nfkappa B subunits in human pancreatic cancer cells. J Surg Res. 2004;118:9–14.PubMedCrossRef
8.
go back to reference Cascinu S, Scartozzi M, Carbonari G, et al. COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. Am J Clin Oncol. 2007;30:526–30.PubMedCrossRef Cascinu S, Scartozzi M, Carbonari G, et al. COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. Am J Clin Oncol. 2007;30:526–30.PubMedCrossRef
9.
go back to reference Weichert W, Boehm M, Gekeler V, et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer. 2007;97:523–30.PubMedCrossRefPubMedCentral Weichert W, Boehm M, Gekeler V, et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer. 2007;97:523–30.PubMedCrossRefPubMedCentral
10.
go back to reference Pan X, Arumugam T, Yamamoto T, et al. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res. 2008;14:8143–51.PubMedCrossRef Pan X, Arumugam T, Yamamoto T, et al. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res. 2008;14:8143–51.PubMedCrossRef
11.
go back to reference Kong R, Sun B, Jiang H, et al. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett. 2010;291:90–8.PubMedCrossRef Kong R, Sun B, Jiang H, et al. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett. 2010;291:90–8.PubMedCrossRef
12.
go back to reference Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res. 2003;9:346–54.PubMed Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res. 2003;9:346–54.PubMed
13.
go back to reference Daniel TS, William WL, Sophie D. TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. J Clin Investig. 2011;121(10):4095–105.CrossRef Daniel TS, William WL, Sophie D. TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. J Clin Investig. 2011;121(10):4095–105.CrossRef
14.
go back to reference Yao Feng, Han Qingqi, Zhong Chenxi, Zhao Heng. TRAF6 promoted the tumorigenicity of esophageal squamous cell carcinoma. Tumor Biol. 2013;34(5):3201–7.CrossRef Yao Feng, Han Qingqi, Zhong Chenxi, Zhao Heng. TRAF6 promoted the tumorigenicity of esophageal squamous cell carcinoma. Tumor Biol. 2013;34(5):3201–7.CrossRef
15.
go back to reference Schneider M, Zimmermann AG, Roberts RA, et al. The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-kappaB. Nat Immunol. 2012;13:823–31.PubMedCrossRefPubMedCentral Schneider M, Zimmermann AG, Roberts RA, et al. The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-kappaB. Nat Immunol. 2012;13:823–31.PubMedCrossRefPubMedCentral
16.
go back to reference Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 2010;17:135–47.PubMedCrossRef Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 2010;17:135–47.PubMedCrossRef
17.
go back to reference Arlt A, Gehrz A, Muerkoster S, et al. Role of NFkappaB and Akt/PI3 K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003;22:3243–51.PubMedCrossRef Arlt A, Gehrz A, Muerkoster S, et al. Role of NFkappaB and Akt/PI3 K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003;22:3243–51.PubMedCrossRef
18.
go back to reference Elisa G, Wang QY, Amir A, et al. Role of cyb5a in pancreatic cancer prognosis and autophagy modulation. J Natl Cancer Inst. 2014;106:1–12.CrossRef Elisa G, Wang QY, Amir A, et al. Role of cyb5a in pancreatic cancer prognosis and autophagy modulation. J Natl Cancer Inst. 2014;106:1–12.CrossRef
19.
go back to reference Sorrentino A, Thakur N, Grimsby S, et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol. 2008;10:1199–207.PubMedCrossRef Sorrentino A, Thakur N, Grimsby S, et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol. 2008;10:1199–207.PubMedCrossRef
20.
go back to reference Ostapoff KT, Kutluk Cenik B, Wang M, et al. Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. Cancer Res. 2014 [Epub ahead of print]. Ostapoff KT, Kutluk Cenik B, Wang M, et al. Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. Cancer Res. 2014 [Epub ahead of print].
Metadata
Title
TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells
Authors
Yefei Rong
Dansong Wang
Wenchuan Wu
Dayong Jin
Tiantao Kuang
Xiaolin Ni
Lei Zhang
Wenhui Lou
Publication date
01-11-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 11/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0260-9

Other articles of this Issue 11/2014

Medical Oncology 11/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.